Despite Hybio Pharmaceutical's recent poor growth, its high ...
Despite Hybio Pharmaceutical's recent poor growth, its high P/S ratio indicates investor optimism for a business turnaround. However, with medium-term revenue decline and expected industry growth of 35%, these prices may not be sustainable. Shareholders may face a tough period unless circumstances improve.
Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Plunge Could Signal Some Risk
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment